Indaptus shares rise 35.90% after-hours on $6M convertible deal with David Lazar, triggering board reshuffle and CEO reassignment.

Indaptus Therapeutics Inc. surged 35.90% in after-hours trading following a $6 million convertible preferred stock deal with David Lazar, a biotech operator with a history of revitalizing underperforming firms. The transaction, which includes a 25% participation right in future offerings and triggers board reshuffles and CEO reassignment, has sparked investor optimism about governance reforms and capital infusion. The deal, announced in a news article noting a 55.9% intraday surge, underscores Lazar’s strategic control and signals a potential operational turnaround. Despite mixed technical indicators and high volatility, the immediate catalyst aligns with the stock’s post-market rally, driven by speculation about improved management and liquidity.